基于生物信息学分析THOC2对卵巢癌预后的诊断价值

邬 舒琪, 路会 侠*
大理大学临床医学院

摘要


目的：探讨THO复合物2（THOC2）在卵巢癌中的表达、临床价值及参与预后的机制。方法：基于TIMER 2.0数据库检索THOC2在肿瘤组织和正常组织中的表达差异；Pan-Cancer Atlas数据库分析THOC2表达与OC患者临床病理分期和总体生存期的相关性；R软件包“clusterProfiler”模块进行GO富集分析和KEGG通路富集分析；“corrplot”进行THOC2和免疫细胞之间的相关性分析；JASPAR数据库识别DEGs构建THOC2基因调控网络。结果：OC组织THOC2表达显著高于正常组织。THOC2高表达组的FPI、OS及生存率高于低表达组；AUC5年、AUC10年分别为0.472、0.409。THOC2被抑制可能导致RNA剪切异常、核质运输障碍、影响基因表达有关。OC中THOC2的表达与肿瘤的免疫细胞浸润有关，抑制THOC2促进OC免疫系统下调或T细胞功能受损。结论：THOC2高表达可能促进OC患者得到更好的预后，可作为免疫治疗的生物标志物或增敏靶点。

关键词


卵巢癌；THO复合物2；预后；诊断价值

全文:

PDF


参考


[1]Jayson CG, Kohn CE, Kitchener CH, et al. Ovarian cancer[J].The Lancet,2014, 384(9951): 1376-1388.

[2]A MR, Patricia E. Ovarian cancer: an overview[J].American family physician,2009,80(6): 609-16.

[3]Zahra M, Mohebat V, Ali H N, et al. Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis[J].BMCCancer,2023,23(1):558-558.

[4]Giuseppe S, Francesco P, Daniela L, et al. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review[J].Expert review of anticancer therapy,2017,17(9):827-839.

[5]Tiefeng C, Wenwei P, Xiaoli S, et al. Increased expression of TET3 predicts unfavorable prognosis in patients with ovarian cancer-a bioinformatics integrative analysis[J].Journal of ovarian research,2019,12(1):101.

[6]Xupeng B, Jie N, Julia B, et al. THOC2 and THOC5 Regulate Stemness and Radioresistance in Triple-Negative Breast Cancer[J].Advanced science (Weinheim, Baden- Wurttemberg, Germany),2021,8(24):e2102658-e2102658.

[7]Chen Y, Chang L, Hu L, et al. Identification of a lactylation-related gene signature to characterize subtypes of hepatocellular carcinoma using bulk sequencing data[J].Journal of gastrointestinal oncology,2024,15(4):1636-1646.

[8]G AF, Patricia K, Myung-Hee K, et al. THO2, a core member of the THO/TREX complex, is required for microRNA production in Arabidopsis[J].The Plant journal : for cell and molecular biology,2015,82(6):1018-1029.

[10]Jun Y L, JinHwa J, DaYoung C, et al. THOC2 expression and its impact on 5-fluorouracil resistance in glioblastoma multiforme[J].American journal of cancer research, 2023,13(6):2410-2425.

[11]Gu XJ, Li YJ, Wang F, Ye T. MiR-30e-3p inhibits gastric cancer development by negatively regulating THO complex 2 and PI3K/AKT/mTOR signaling[J]. World J Gastrointest Oncol. 2022 Nov 15;14(11):2170-2182.

[12]Ye Z, Bing A, Zhao S, et al. Comprehensive analysis of spliceosome genes and their mutants across 27 cancer types in 9070 patients: clinically relevant outcomes in the context of 3P medicine[J].EPMA J. 2022 May 10;13(2):335-350.

[13]Guodong Z, Qing X, Xiangyun Z, et al. Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer[J].Cancer medicine,2021,10(12):3905-3918.

[14]Minato H, Gaddiel G, Chloe N, et al. The RNA helicase DDX39B activates FOXP3 RNA splicing to control T regulatory cell fate[J].eLife,2023,12.

[15]Zhanzhan X, Xiaoman L, Hanxiao L, et al. Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA[J]. Oncogene,2020,39(47):7051-7062.

[16]Peixian Z, Na L, Xianquan Z.Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis[J].Frontiers in Endocrinology,2022, 13972341-972341.


Refbacks

  • 当前没有refback。